Meet The Team • K2 Medical Research ...

Dr. Nicholas Weber, DO

Claim this profile

K2 Medical Research

Studies Alzheimer's Disease
Studies Dementia
11 reported clinical trials
12 drugs studied

Area of expertise

1Alzheimer's Disease
Nicholas Weber, DO has run 9 trials for Alzheimer's Disease. Some of their research focus areas include:
ApoE positive
ApoE negative
2Dementia
Nicholas Weber, DO has run 3 trials for Dementia.

Affiliated Hospitals

Image of trial facility.
K2 Medical Research
Image of trial facility.
K2 Medical Research Winter Garden

Clinical Trials Nicholas Weber, DO is currently running

Image of trial facility.

Biomarker Database

for Alzheimer's Disease

Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective. Digital biomarkers and blood-based biomarkers will be tested to determine whether a meaningful relationship exists between biomarkers alone or in combination with tau or amyloid brain pathology identified through PET images.
Recruiting1 award N/A10 criteria
Image of trial facility.

Brentuximab Vedotin

for Hodgkin Lymphoma

RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New Zealand. Trial 2 will be led by the Canadian Cancer Trials Group (CCTG) and conducted in North America, with CCTG the regulatory sponsor in Canada, and University of Miami the regulatory sponsor and IND holder in the US. Datasets from Trial 1 and Trial 2 will be combined to achieve the total sample size. Data analysis will be performed by UCL and therefore UCL is responsible for the clinicaltrials.gov entry. Eligible patients will be randomised to receive either ABVD or A2VD chemotherapy. An interim PET-CT scan will be performed after 2 cycles of treatment, which will be used to adapt subsequent treatment. Patients will receive a total of 3-4 cycles of chemotherapy and may also receive involved site radiotherapy as consolidation. Patients will be followed up for a minimum of 5 years after treatment.
Recruiting2 awards Phase 313 criteria

More about Nicholas Weber, DO

Clinical Trial Related5 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Nicholas Weber, DO has experience with
  • Placebo
  • Donanemab
  • Piromelatine 20 Mg
  • Simufilam
  • Buntanetap
  • ATH-1017

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Nicholas Weber, DO specialize in?
Is Nicholas Weber, DO currently recruiting for clinical trials?
Are there any treatments that Nicholas Weber, DO has studied deeply?
What is the best way to schedule an appointment with Nicholas Weber, DO?
What is the office address of Nicholas Weber, DO?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security